A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma

被引：0

作者：

Soushi Ibata

Tsutomu Sato

Hiroyuki Kuroda

Yasuhiro Nagamachi

Satoshi Iyama

Akihito Fujimi

Yusuke Kamihara

Yuichi Konuma

Masahiro Yoshida

Ayumi Tatekoshi

Akari Hashimoto

Hiroto Horiguchi

Kaoru Ono

Kazuyuki Murase

Kohichi Takada

Koji Miyanishi

Masayoshi Kobune

Yasuo Hirayama

Junji Kato

机构：

[1] Sapporo Medical University School of Medicine,Department of Medical Oncology and Hematology

[2] Steel Memorial Muroran Hospital,Gastroenterology and Hematology/Clinical Oncology, Internal Medicine

[3] Kiyota Hospital,Department of Hematology

[4] Oji General Hospital,Department of Hematology and Oncology

[5] Asahikawa Red Cross Hospital,Department of Hematology and Oncology

[6] Higashi Sapporo Hospital,Division of Internal Medicine

来源：

Cancer Chemotherapy and Pharmacology | 2016年 / 78卷

关键词：

Multiple myeloma; Consolidation/maintenance; Bortezomib; Lenalidomide; Dexamethasone; VRD;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1041 / 1049

页数：8

共 50 条

[21] A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
Richardson, Paul G.
Xie, Wanling
Jagannath, Sundar
Jakubowiak, Andrzej
Lonial, Sagar
Raje, Noopur S.
Alsina, Melissa
Ghobrial, Irene M.
Schlossman, Robert L.
Munshi, Nikhil C.
Mazumder, Amitabha
Vesole, David H.
Kaufman, Jonathan L.
Colson, Kathleen
McKenney, Mary
Lunde, Laura E.
Feather, John
Maglio, Michelle E.
Warren, Diane
Francis, Dixil
Hideshima, Teru
Knight, Robert
Esseltine, Dixie-Lee
Mitsiades, Constantine S.
Weller, Edie
Anderson, Kenneth C.
BLOOD, 2014, 123 (10) : 1461 - 1469
[22] A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma
White, Darrell J.
Bahlis, Nizar J.
Venner, Christopher P.
Schiller, Gary J.
Gasparetto, Cristina J.
Sutherland, Heather J.
Sebag, Michael
Lentzsch, Suzanne
Kotb, Rami
Bensinger, William
Lipe, Brea C.
Chen, Christine I.
Del Col, Aldo
Kauffman, Michael G.
Shacham, Sharon
Jeha, Jacqueline
Saint-Martin, Jean-Richard
Shah, Jatin
LeBlanc, Richard
BLOOD, 2017, 130
[23] Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study
Roussel, Murielle
Avet-Loiseau, Herve
Moreau, Philippe
Huynh, Anne
Benboubker, Lotfi
Hulin, Cyrille
Marit, Gerald
Leleu, Xavier
Pegourie, Brigitte
Fruchart, Christophe
Caillot, Denis
Stoppa, Anne-Marie
Facon, Thierry
Harousseau, Jean-Luc
Attal, Michel
BLOOD, 2010, 116 (21) : 274 - 275
[24] Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy
Voorhees, Peter M.
Laubach, Jacob
Anderson, Kenneth C.
Richardson, Paul G.
BLOOD, 2013, 121 (05) : 858 - 858
[25] Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Kaufman, Jonathan L.
Mina, Roberto
Shah, Jatin J.
Laubach, Jacob P.
Nooka, Ajay K.
Lewis, Colleen
Gleason, Charise
Sharp, Cathy
Harvey, R. Donald
Heffner, Leonard T.
Richardson, Paul
Lonial, Sagar
Orlowski, Robert Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (12): : 797 - 803
[26] A phase I/II trial of bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma.
Popat, Rakesh
Williams, Catherine
Cook, Mark
Craddock, Charles
Basu, Supratik
Singer, Charles
Odeh, Liz
Foot, Nicola
Oakervee, Heather
Cavenagh, James D.
BLOOD, 2006, 108 (11) : 1011A - 1011A
[27] Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma
Broijl, Annemiek
Kersten, Marie Jose
Alemayehu, Wendim Ghidey
Levin, Mark-David
de Weerdt, Okke
Vellenga, Edo
Meijer, Ellen
Wittebol, Shulamiet
Ghiraw-Visser, Rosita
Stevens-Kroef, Marian
Beverloo, Berna
Bos, Gerard M. J.
Wijermans, Pierre W.
Lokhorst, Henk
Sonneveld, Pieter
BLOOD, 2014, 124 (21)
[28] ESCALATED WEEKLY DOSE OF BORTEZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE MAINTENANCE IN FIRST RELAPSE OF MULTIPLE MYELOMA. INTERIM ANALYSIS OF THE HOVON 86 TRIAL
Sonneveld, P.
De Weerdt, O.
Levin, M.
Ghidey, W.
Vellenga, E.
Wittebol, S.
Doorduijn, J.
Wijermans, P.
Kersten, M. J.
Bos, G.
Lokhorst, H.
HAEMATOLOGICA, 2012, 97 : 117 - 117
[29] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
Yasuo Mori
Ilseung Choi
Goichi Yoshimoto
Tsuyoshi Muta
Satoshi Yamasaki
Kazuki Tanimoto
Tomohiko Kamimura
Hiromi Iwasaki
Ryosuke Ogawa
Koichi Akashi
Toshihiro Miyamoto
International Journal of Hematology, 2020, 111 : 673 - 680
[30] Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma
O'Gorman, Peter
Laubach, Jacob P.
O'Dwyer, Michael E.
Krawczyk, Janusz
Yee, Andrew J.
Gilligan, Oonagh
Cahill, Mary R.
Rosenblatt, Jacalyn
Quinn, John
Murphy, Philip T.
DiPietro, Heidi
Perera, Meegahage Ratnakanthi
Crotty, Gerard M.
Cummings, Kristen
Hayden, Patrick J.
Browne, Paul
Savell, Alexandra
O'Leary, Hilary M.
O'Keeffe, Denis
Masone, Kelly
Hennessy, Brian J.
Garcia, Thomas Guerrero
Scott, Kathleen
Saeed, Khalid
Bianchi, Giada
Dowling, Paul
Tierney, Ciara
Richardson, Paul G.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (05) : 562 - 573

← 1 2 3 4 5 →